Use of Topiramate in Preventing Pediatric Migraine

Marcia L. Buck, Pharm.D., FCCP, FPPAG


Pediatr Pharm. 2013;19(7) 

In This Article


Migraines affect 3–11% of children and may impact school performance, social interactions, and family life. Current therapies for migraine prophylaxis include tricyclic antidepressants, β-blockers, calcium channel blockers, antihistamines, and the antiseizure medications valproic acid and topiramate. Topiramate was approved by the Food and Drug Administration (FDA) in 1996 as an antiseizure medication and later found to be an effective therapy for the prevention of migraines. Based on clinical trials in adults, the FDA approved an indication for migraine prophylaxis in 2004. Although not yet approved for this use in children, topiramate has shown promise as a means of preventing migraines in the pediatric population as well.[1,2]